← Back to Search

Sulfur Colloid SPECT/CT for Liver Cancer

Led By Smith Apisarnthanarax
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a diagnosis of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, or metastatic liver cancer planned to receive definitive doses of radiation or surgical resection are eligible
Measurable hepatic disease and/or presence of vascular tumor thrombosis
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Upup to 1 month
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is studying how well SPECT/CT with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer.

Eligible Conditions
  • Blood Clot
  • Liver Cancer
  • Intrahepatic Cholangiocarcinoma

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have liver cancer and are planning to have radiation treatment or surgery.
You have liver disease that can be measured, or a blood clot in a blood vessel near a tumor.
You should have had a CT or MRI scan within 2 months before joining the study.
You can have had different types of treatments before joining the study, including chemotherapy and radiation at the same time.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Sulfur colloid (SC) uptake on single photon emission computed tomography/computed tomography (SPECT/CT) imaging
Secondary outcome measures
Changes in sulfur colloid uptake in single photon emission computed tomography/computed tomography imaging

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (SC SPECT/CT)Experimental Treatment3 Interventions
There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol. In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT. In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans.
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
Completed Phase 2
Single Photon Emission Computed Tomography
Completed Phase 4
Technetium Tc-99m Sulfur Colloid

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,696 Previous Clinical Trials
1,687,959 Total Patients Enrolled
Smith ApisarnthanaraxPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium

Media Library

Single Photon Emission Computed Tomography Clinical Trial Eligibility Overview. Trial Name: NCT02881554 — N/A
Blood Clot Research Study Groups: Diagnostic (SC SPECT/CT)
Blood Clot Clinical Trial 2023: Single Photon Emission Computed Tomography Highlights & Side Effects. Trial Name: NCT02881554 — N/A
Single Photon Emission Computed Tomography 2023 Treatment Timeline for Medical Study. Trial Name: NCT02881554 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you elaborate on past research involving Single Photon Emission Computed Tomography?

"Currently, 4 investigations investigating Single Photon Emission Computed Tomography are in progress with 1 study being in its concluding Phase 3. Santa Monica is a hub for these experiments; however, there are 7 distinct centres currently running trials concerning this imaging technique."

Answered by AI

How many participants is the study looking to recruit?

"Correct. Records on clinicaltrials.gov demonstrate that this scientific investigation, which was originally posted in December 2016, is actively recruiting participants. In total, 60 individuals need to be registered from 2 different medical facilities."

Answered by AI

In what scenarios is Single Photon Emission Computed Tomography typically employed?

"Single Photon Emission Computed Tomography is a commonly prescribed intervention for hypovolaemia. It may also be used to assess drainage procedure, pulmonary aspiration of gastric contents, and functioning reticuloendothelial cells in the liver, spleen and bone marrow."

Answered by AI

Is this particular experiment a pathbreaking endeavor?

"Since 2008, Single Photon Emission Computed Tomography has been the object of rigorous clinical studies. The very first study was funded by NuRx Pharmaceuticals, Inc., and enrolled 65 participants. After receiving Phase 2 drug approval in 2008, it is now being tested across 5 cities located within one nation through 4 separate trials."

Answered by AI

Are recruitment efforts still underway for this clinical trial?

"Indeed, the details posted on clinicaltrials.gov demonstrate that this trial is now enlisting volunteers. The study was initially put up on December 21st 2016 and recently modified on August 16th 2022; they are seeking 60 participants from two different facilities."

Answered by AI
~18 spots leftby Dec 2026